We’ve long trusted the FDA to protect public health, but is this safeguard wavering? Our expert this week explains why premarket review isn’t as effective as it once was, how corporations have leveraged loopholes to skirt around regulations, and how the agency can get back on track.
Guest Information:
- Daniel Aaron, Associate Professor of Law, S.J. Quinney College of Law University of Utah, FDA Researcher
Leave a Reply